Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers

Z

Zagazig University

Status and phase

Completed
Phase 2

Conditions

Non-melanoma Skin Cancers

Treatments

Drug: Methotrexate

Study type

Interventional

Funder types

Other

Identifiers

NCT05315128
IRB# 6029/-6-7-2020

Details and patient eligibility

About

to compare the effectiveness and safety of intralesional vs. systemic MTX in NMSC management

Full description

Intralesional methotrexate (MTX) could to be promising conservative alternative for non-melanoma skin cancer (NMSC). Systemic MTX was attempted as adjuvant for locally-advanced NMSC.

Enrollment

60 patients

Sex

All

Ages

20 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

• Adult patients of both sexes with histologically-confirmed primary or recurrent non- metastatic NMSCs of different types (BCC,SCC, and/or KA), sites, number, sizes and duration were included in the study.

Exclusion criteria

• Hypersensitivity reactions to methotrexate, liver or kidney disease, immunosuppressive conditions, HIV, HBV, and HCV infection, hematological abnormalities and metastasis. Pregnant or lactating women, females in their child-bearing period not using or refusing contraceptive methods, and those who had any other form of NMSC management in the month preceding enrollment.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

60 participants in 2 patient groups

Intralesional methotrexate
Active Comparator group
Description:
Group A 30 patients received intralesional injection of MTX with an insulin syringe into the tumor at a dose ranging between 12.5 mg to 25 mg according to the tumor size every week until complete improvement or for a maximum of 8 sessions.
Treatment:
Drug: Methotrexate
Intramuscular methotrexate
Active Comparator group
Description:
Group B 30 patients received systemic MTX (SC, or IM) was injected at a dose of 25 mg every week until clearance or for a maximum of 8 sessions.
Treatment:
Drug: Methotrexate

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems